This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jordan, M. K.
Right arrow Articles by Piscitelli, S. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jordan, M. K.
Right arrow Articles by Piscitelli, S. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2004, p. 635-637, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.635-637.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Plasma Pharmacokinetics of Sulfadiazine Administered Twice Daily versus Four Times Daily Are Similar in Human Immunodeficiency Virus-Infected Patients{dagger}

M. Kelli Jordan,1 Aaron H. Burstein,1,{ddagger} Diane Rock-Kress,2 Raul M. Alfaro,1 Alice K. Pau,1,3 Joseph A. Kovacs,2* and Stephen C. Piscitelli1,3

Pharmacy Department,1 Critical Care Medicine Department, Clinical Center,2 Office of Clinical Research, National Institutes of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland3

Received 1 July 2003/ Returned for modification 2 September 2003/ Accepted 28 October 2003

The pharmacokinetics of 2,000 mg of sulfadiazine administered twice daily (BID) versus those of 1,000 mg administered four times a day were compared in eight human immunodeficiency virus-infected patients. No differences in pharmacokinetic parameters were detected between the regimens. These data provide a pharmacokinetic rationale for BID dosing of sulfadiazine for the treatment and suppression of toxoplasmosis.

* Corresponding author. Mailing address: Critical Care Medicine Department, Warren Grant Magnuson Clinical Center, Bldg. 10, Room 7D43, MSC 1662, National Institutes of Health, Bethesda, MD 20892-1662. Phone: (301) 496-9907. Fax: (301) 402-1213. E-mail: jkovacs{at}nih.gov.

{dagger} This paper is dedicated to the memory of Muriel Kelli Jordan.

{ddagger} Present address: Pfizer Global Research, Groton, Conn.

§ Present address: GlaxoSmithKline, Research Triangle Park, N.C.

Antimicrobial Agents and Chemotherapy, February 2004, p. 635-637, Vol. 48, No. 2
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.2.635-637.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.





Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»